Aminoglycosides pharmacogenetic testing webinar

In January 2021 the MHRA released a drug safety update on the increased risk of deafness due to a mitochondrial genetic variant when patients are treated with a class of antibiotics called aminoglycosides. This pharmacogenetic test is available on the National Genomic Test Directory if the eligibility criteria are met.

This webinar by the North Thames Genomic Medicine Service covers the following:

• The mechanism of aminoglycoside inducted deafness due to m.1555A>G
• How the test is currently being used
• The limitations and governance considerations when implementing testing
• Future technology e.g., point of care testing

Download a copy of the presentation slides here.

To find out more about Aminoglycosides best practice recommendations click here